

# Synopsis of Membership Considerations

---

For Membership, evidence of high achievement in each category is necessary. Associate Membership is evaluated using the same criteria as for full membership, except early levels of achievement are expected. However, evidence of quality to date in all categories should be present, and a trajectory of future excellence should be apparent in each category.

The below priority ratings are assessed based on extent of achievement in each category and relative to the nominee pool.

## Scientific Productivity Category:

1. Publications in peer-reviewed journals, including high relative impact of the publications as ascertained using journal impact factors and the “H-index”.  
and/or
2. Demonstrated significant role in achievement of meaningful milestones in drug discovery and development, e.g., patents, preclinical candidate-compound transition to IND, drug progression in clinical phases to NDA, etc.

## Scientific & Generative Leadership Category:

1. Evidence of extramural funding. While renewable NIH funding is highly valued, other forms of research funding also are considered.  
and/or
2. Evidence of effective program leadership resulting in major milestone achievements in pharmaceutical preclinical and clinical development  
and/or
3. Evidence for significant role in creation and leadership of innovative research and funding programs within government institutions

## Distinctions & Organizations Category:

1. Awards and honors
2. Roles in national and international research organizations
3. Editorial boards
4. Membership on grant review panels, especially NIH study sections

## Commitment to ACNP Category (past, present, future):

1. Strength of nomination letters attesting to the present and future value of the candidate to ACNP
2. Record of reviewing for Neuropsychopharmacology when asked
3. Past record of ACNP participation (panels, posters, attendance)

## Mentorship Category:

1. Record of training students, fellows and/or faculty (or equivalent)